GlycoMimetics, Inc. (GLYC)
After hours:
- Business Wire
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
ROCKVILLE, Md., June 04, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced comprehensive results from the company’s pivotal Phase 3 study of uproleselan in R/R AML.
- Business Wire
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
ROCKVILLE, Md., May 29, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced that it will host a key opinion leader event on Tuesday, June 4, 2024, at 8:30am ET to provide a comprehensive overview of data from the company’s pivotal Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML).
- Business Wire
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
ROCKVILLE, Md., May 06, 2024--GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced topline results from its Phase 3 global pivotal study of uproleselan in 388 patients with R/R AML. In the study, uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemothera
